KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non-Current Debt (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 15 years of Non-Current Debt data on record, last reported at $4.3 billion in Q4 2025.

  • For Q4 2025, Non-Current Debt fell 28.78% year-over-year to $4.3 billion; the TTM value through Dec 2025 reached $4.3 billion, down 28.78%, while the annual FY2025 figure was $4.3 billion, 28.78% down from the prior year.
  • Non-Current Debt reached $4.3 billion in Q4 2025 per JAZZ's latest filing, roughly flat from $4.3 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $6.5 billion in Q2 2021 and bottomed at $1.9 billion in Q1 2021.
  • Average Non-Current Debt over 5 years is $5.3 billion, with a median of $5.7 billion recorded in 2023.
  • Peak YoY movement for Non-Current Debt: skyrocketed 238.85% in 2021, then decreased 28.78% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $6.0 billion in 2021, then decreased by 5.41% to $5.7 billion in 2022, then fell by 10.28% to $5.1 billion in 2023, then increased by 18.98% to $6.1 billion in 2024, then fell by 28.78% to $4.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $4.3 billion in Q4 2025, $4.3 billion in Q3 2025, and $4.3 billion in Q2 2025.